Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism

The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypogonadism Endocrine System Diseases Gonadal Disorders

Age range

20 year–25 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Aydoğan AYDOĞDU

Ankara, 06600, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Volunteers patients with hypogonadism

Exclusion criteria

Coronary heart disease
Other pituitary/hypothalamic disorders or other non-hypogonadism diseases
None was receiving vitamins, lipid-lowering drugs, or other medications known to interfere with PON1 activity, lipid profile, or gonadal function

Treatment and study plan

Sustanon

Drug

250 mg/21 days

Other names: no name

Primary outcomes

paraoxonase level after testosterone treatment

Sponsors and collaborators

Lead sponsor

Gulhane School of Medicine

Other

Registry information

Official study title

Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism

Important dates

Study start: 2008
Primary completion: 2009
Study completion: 2009
First posted: Apr 20, 2010
Registry last updated: Apr 20, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed